Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells

Journal of Oral Pathology and Medicine

Volumn 42, Issue 4, 2013, Pages 332-338

  Jameson, Mark J ^a   Taniguchi, Linnea E ^a   Vankoevering, Kyle K ^a   Stuart, Menachem M ^a   Francom, Christian R ^a   Mendez, Rolando E ^a   Beckler, Andrew D ^a,c   Carlson, Hans T ^a   Thomas, Christopher Y ^b,d   Khalil, Ashraf A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle regulation; Cyclin dependent kinase inhibitor; Growth factor; Oral cavity cancer; Therapeutic resistance

Indexed keywords

CYCLIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN P27; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C RECEPTOR;

ARTICLE; CARCINOMA CELL; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL MOTILITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INDUCED RESISTANCE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN D; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MOUTH NEOPLASMS; ONCOGENE PROTEIN V-AKT; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; S PHASE; SUBCELLULAR FRACTIONS;

EID: 84875805011     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12014     Document Type: Article

References (19)

1. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-65.
2. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003; 195: 139-50.
3. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science 1993; 260: 536-9.
4. Mineta H, Miura K, Suzuki I, et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 1999; 85: 1011-7.
5. Kuo MY, Hsu HY, Kok SH, et al. Prognostic role of p27(Kip1) expression in oral squamous cell carcinoma in Taiwan. Oral Oncol 2002; 38: 172-8.
6. Venkatesan TK, Kuropkat C, Caldarelli DD, et al. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 1999; 109: 1329-33.
7. Tamura N, Dong Y, Sui L, et al. Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas. J Laryngol Otol 2001; 115: 400-6.
8. Mineta H, Miura K, Suzuki I, et al. p27 expression correlates with prognosis in patients with hypopharyngeal cancer. Anticancer Res 1999; 19: 4407-12.
9. Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 2011; 17: 12-8.
10. Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 2009; 8: 3455-61.
11. Kim J, Jonasch E, Alexander A, et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009; 15: 81-90.
12. Jameson MJ, Beckler AD, Taniguchi LE, et al. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther 2011; 10: 2124-34.
13. Slomiany MG, Black LA, Kibbey MM, Tingler MA, Day TA, Rosenzweig SA. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 2007; 248: 269-79.
14. Rasamny JJ, Allak A, Krook KA, et al. Cyclin D1 and FADD as Biomarkers in Head and Neck Squamous Cell Carcinoma. Otolaryngol Head Neck Surg 2012; 146: 923-31.
15. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-52.
16. Qi CF, Xiang S, Shin MS, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res 2006; 30: 153-63.
17. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136-44.
18. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-67.
19. Perisanidis C, Perisanidis B, Wrba F, et al. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 2012; 41: 40-6.